Recevez les dernières nouvelles sur l'action Adicet Bio avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de ACET

Dernières nouvelles pour

ADICET BIO INC

Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Inc

Press Releases

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

ACET

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Alpha Cognition

Agenus

Alector

Anika Therapeutics

Anixa Biosciences

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Compugen

Climb Bio

Cardiff Oncology

Citius Oncology

Elicio Therapeutics

Forte Biosciences

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Seres Therapeutics

MDxHealth

Molecular Partners AG - American Depositary Shares

Molecular Partners

Oncolytics Biotech

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Spero Therapeutics

TScan Therapeutics

Instil Bio

Tevogen Bio Holdings

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Guggenheim

HC Wainwright & Co.

Wedbush

Jones Trading

Aceto Corporation

Comments

Adicet Bio Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL